WCLC 2019 Archives - Medical Conferences

Home > Oncology > WCLC 2019

World Conference on Lung Cancer

07–10 September 2019 Barcelona, Spain

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By

Prof. Scott Gettinger, Yale Cancer Center, USA

Screening, Detection, and Diagnosis

Tumour mutation score is a better predictor than TMB

New technologies in lung cancer detection

Non-Small-Cell Lung Cancer

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By

Prof. Scott Gettinger, Yale Cancer Center, USA

Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression

pTMB is a feasible predictive biomarker for chemoimmunotherapy

Promising phase 1 results of novel KRAS-inhibitor in NSCLC

Presented By

Dr Ramaswamy Govindan, Washington University School of Medicine, USA

Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA

High need for biomarkers for stage III lung cancer

CAR T cell therapy in lung adenocarcinoma may be beneficial, but still early days

Other Thoracic Malignancies

Durvalumab added to etoposide improves outcomes in ES-SCLC

Talazoparib + low-dose temozolomide seems promising in ES-SCLC

New targets in thymic epithelial tumours may aid in identifying treatment options

Novel targets in mesothelioma may aid in developing treatment strategies

Immuno-Oncology

BMI and age do not influence survival/irAEs in patients treated with immune checkpoint inhibitors

Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities

Presented By

Dr Fabrice Barlesi, Hôpitaux de Marseille, France

Tackling immunotherapy resistance

Targeted Therapy

Older age and low neutrophilia inflammation predictor for osimertinib efficacy

EGFR TKI retreatment effective after earlier discontinuation

Phase 3 Trial Updates

First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

Presented By

Dr Martin Reck, Lung Clinic Grosshansdorf, Germany

Medical Conferences

WCLC 2019

Table of Contents

Featured articles

Letter from the Editor

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Screening, Detection, and Diagnosis

Tumour mutation score is a better predictor than TMB

New technologies in lung cancer detection

Non-Small-Cell Lung Cancer

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression

pTMB is a feasible predictive biomarker for chemoimmunotherapy

Promising phase 1 results of novel KRAS-inhibitor in NSCLC

Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer

High need for biomarkers for stage III lung cancer

CAR T cell therapy in lung adenocarcinoma may be beneficial, but still early days

Other Thoracic Malignancies

Durvalumab added to etoposide improves outcomes in ES-SCLC

Talazoparib + low-dose temozolomide seems promising in ES-SCLC

New targets in thymic epithelial tumours may aid in identifying treatment options

Novel targets in mesothelioma may aid in developing treatment strategies

Immuno-Oncology

BMI and age do not influence survival/irAEs in patients treated with immune checkpoint inhibitors

Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities

Tackling immunotherapy resistance

Targeted Therapy

Older age and low neutrophilia inflammation predictor for osimertinib efficacy

EGFR TKI retreatment effective after earlier discontinuation

Phase 3 Trial Updates

First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC

Less focus on quality of life in recent phase 3 trials